TP53 and acute myeloid leukemia: Moreover, the landmark VIALE-A trial investigating VA in newly diagnosed AML revealed striking differential responses based on TP53 status: whereas no responses (0%) were observed in TP53-mutated patients receiving azacitidine monotherapy, the VA regimen achieved a response rate of 55.3% (95% CI, 38.3–71.4) in this high-risk population [16].